Investor Relations

About AVROBIO

Our mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing a program in Pompe disease. AVROBIO is powered by the plato™ gene therapy platform, our foundation designed to scale gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.

Sign up for email alerts

Stock Chart


Copyright West LLC. Minimum 15 minutes delayed.

Events & Presentations

Our News Latest press releases

Apr 03, 2020

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2020-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Read More

Mar 30, 2020

AVROBIO Outlines Response to COVID-19 and Current Assessment of Business Impact

Patient identification for clinical trials continues; dosing temporarily paused as clinical trial sites focus on COVID-19 pandemic Essential laboratory and manufacturing activities currently uninterrupted Cash runway into Q2 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 30, 2020-- AVROBIO, Inc.

Read More

Mar 26, 2020

AVROBIO to Participate in Upcoming April Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will participate at three upcoming virtual

Read More

See All

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.